Impact of baseline hepatitis B viremia and management on outcomes in patients (Pts) with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP): Outcomes from REACH-2.

Peter R. Galle,Masatoshi Kudo,Josep M. Llovet,Richard S. Finn,Mark Karwal,Denis Pezet,Tae-You Kim,Tsai-Sheng Yang,Vittorina Zagonel,Jiri Tomasek,Jean-Marc Phelip,Yann Touchefeu,Su Jin Koh,Guido Stirnimann,Chunxiao Wang,Kenyon Ogburn,Paolo Abada,Ryan C. Widau,Andrew X. Zhu

Impact of baseline hepatitis B viremia and management on outcomes in patients (Pts) with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP): Outcomes from REACH-2.

2020

Peter R. Galle
Masatoshi Kudo
Josep M. Llovet
Richard S. Finn
Mark Karwal
Denis Pezet
Tae-You Kim
Tsai-Sheng Yang
Vittorina Zagonel
Jiri Tomasek
Jean-Marc Phelip
Yann Touchefeu
Su Jin Koh
Guido Stirnimann
Chunxiao Wang
Kenyon Ogburn
Paolo Abada
Ryan C. Widau
Andrew X. Zhu

569Background: REACH (NCT01140347) and REACH-2 (NCT02435433) were global, randomized, blinded, placebo (PL)-controlled phase 3 trials of ramucirumab (RAM) in pts with advanced HCC following sorafen...

Keywords:

Hepatocellular carcinoma
Elevated alpha-fetoprotein
Gastroenterology
Viremia
Internal medicine
Medicine
Hepatitis B
Pathology
in patient
Placebo
Ramucirumab

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations